Moderna, Inc. (MRNA)
After hours:
| Previous close | 150.88 |
| Open | 149.80 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 145.36 - 150.36 |
| 52-week range | 115.03 - 217.25 |
| Volume | |
| Avg. volume | 3,661,123 |
| Market cap | 57.215B |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | 7.55 |
| EPS (TTM) | 19.64 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 226.64 |
- Motley Fool
Could CRISPR Therapeutics Become the Next Moderna?
CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA). Today, CRISPR's market value sits at about $3.4 billion. Since, Moderna has grown to become a $58 billion company, with a blockbuster product and three more potential ones on the horizon.
- Motley Fool
3 Things About Moderna That Smart Investors Know
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.
- Zacks
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
